NCT06341335View on ClinicalTrials.gov

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

July 31, 2027

Conditions
Gastric and Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

cadonilimab

iv, q3w

DRUG

pulocimab

iv, q3w

DRUG

paclitaxel

iv, q3w

DRUG

placebo

iv, q3w

Trial Locations (1)

Unknown

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY